Management of Fosamax Discontinuation Before Dental Treatment

Introduction to Fosamax and Dental Treatment

• The American Society of Clinical Oncology suggests that there is insufficient evidence to definitively support routine discontinuation of Fosamax before dental procedures, though some experts suggest a 2-month drug holiday may allow better bone healing, with resumption delayed until complete mucosal healing occurs 1

Evidence-Based Risk Context

• The risk of medication-related osteonecrosis of the jaw (MRONJ) with oral bisphosphonates like Fosamax for osteoporosis is extremely low at less than 1 case per 100,000 person-years, which contrasts dramatically with intravenous bisphosphonates used in cancer treatment, which carry a 6.7-11% incidence 2

The Drug Holiday Controversy

• Bisphosphonates have an extremely long bone half-life, persisting for years after stopping treatment, suggesting a short drug holiday may provide no protective benefit, as stated by the Journal of Clinical Oncology 1, 3
• The 2019 MASCC/ISOO/ASCO guideline explicitly states there is insufficient evidence to support or refute the need for discontinuation before dentoalveolar surgery, according to the American Society of Clinical Oncology 1

Recommended Clinical Algorithm

• Complete comprehensive dental evaluation including orthopantomography and intraoral radiographs before starting bisphosphonate therapy, as recommended by the American Society of Clinical Oncology 4, 1
• Elective dentoalveolar surgical procedures should not be performed during active therapy, as stated by the American Society of Clinical Oncology 1
• Maintain dental check-ups every 6 months once therapy has commenced, and address modifiable risk factors, according to the American Society of Clinical Oncology 4, 1

Critical Caveats

• The decision to discontinue must balance MRONJ risk against the risk of osteoporotic fractures during the drug holiday, as stated by the American Society of Clinical Oncology 1
• At least 60% of MRONJ cases occur after dentoalveolar surgery, particularly tooth extractions, making the timing of dental procedures critical, according to the American Society of Clinical Oncology 4, 3

Common Pitfalls to Avoid

• Do not confuse the low risk in osteoporosis patients with the much higher risk in cancer patients receiving high-dose intravenous bisphosphonates, as stated by the National Comprehensive Cancer Network 2

Management of Bisphosphonate Therapy in Dental Procedures

Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ)

• Bisphosphonates like Fosamax (alendronate) are associated with medication-related osteonecrosis of the jaw (MRONJ), a serious complication characterized by exposed bone in the maxillofacial region 5, 6
• Risk factors for MRONJ include invasive dental procedures, particularly tooth extractions, and poor oral health and periodontitis 5, 7

Recommendations for Dental Procedures

• Comprehensive dental evaluation including radiographic examination should be performed before starting bisphosphonate therapy, according to the American College of Clinical Oncology 5, 8
• Necessary dental procedures should be completed before initiating bisphosphonate treatment, as recommended by the National Comprehensive Cancer Network 8, 9
• Elective dentoalveolar surgical procedures (extractions, implants) should be avoided during active therapy with bisphosphonates when possible, as suggested by the American College of Clinical Oncology 6, 10

Duration of Drug Holiday

• Some clinicians recommend a 2-month drug holiday before invasive dental procedures, with resumption of therapy delayed until adequate healing has occurred 8, 11
• The American College of Clinical Oncology suggests that the decision to discontinue therapy must balance the risk of MRONJ against the risk of fractures or other skeletal events that might occur during the drug holiday 8, 12

Important Considerations and Caveats

• Patients should maintain excellent oral hygiene and receive regular dental check-ups (every 6 months) while on bisphosphonate therapy, as recommended by the American College of Clinical Oncology and the National Comprehensive Cancer Network 5, 9
• Post-procedure follow-up should be scheduled every 6-8 weeks until complete mucosal healing has occurred, according to the American College of Clinical Oncology 6

Dental Restorative Care in Patients Receiving Intravenous Zoledronic Acid (Zometa)

Risk Stratification of Dental Procedures

• High‑risk (invasive) procedures such as tooth extractions, dental implant placement, bone grafting, or any surgery that manipulates bone should be avoided during active Zometa therapy because at least 60 % of medication‑related osteonecrosis of the jaw (MRONJ) cases follow dentoalveolar surgery. [NCCN] 13
• Low‑risk (non‑invasive) procedures including crown preparation, impressions, and routine fillings that do not penetrate bone or cause extensive soft‑tissue trauma can be performed safely without a drug holiday. [NCCN] [13][14]
• The incidence of MRONJ in cancer patients receiving intravenous bisphosphonates (Zometa) is 6.7 %–11 %, markedly higher than the < 1 case per 100 000 person‑years observed with oral bisphosphonates for osteoporosis. [NCCN] [13][15]

Management of Non‑Invasive Restorative Procedures

• Proceed with crown placement and partial impressions without interrupting Zometa therapy. [NCCN] [13][14]
• Maintain excellent oral hygiene throughout the procedure to minimise mucosal irritation. [NCCN] [13][14]15
• Use atraumatic techniques to avoid soft‑tissue trauma during impression taking and crown preparation. [NCCN] 13
• Schedule dental check‑ups every 6 months for patients on bisphosphonate therapy to monitor oral health status. [NCCN] 15

Recommendations If Invasive Dental Work Becomes Necessary

• Perform a comprehensive dental evaluation, including radiographic imaging, before any bone‑invasive procedure. [NCCN] 13
• Some experts advise a 2‑month drug holiday prior to invasive surgery, but the evidence supporting this practice is limited and remains controversial. [NCCN] 13
• Ensure patients are supplemented with calcium (≈ 500 mg daily) and vitamin D (≈ 400 IU daily) and correct any vitamin D deficiency before surgery to reduce the risk of hypocalcaemia. [NCCN] 13

Monitoring and Patient Education

• After restorative work, monitor for soft‑tissue trauma, delayed healing, or exposed bone and intervene promptly if such signs appear. [NCCN] [13][15]
• Educate patients to report persistent pain, swelling, or non‑healing areas immediately, facilitating early detection of complications. [NCCN] 13